Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GENOMIC VISION |
Real-time
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.001800 EUR | +5.88% | -.--% | -95.01% | |
| Nov. 14 | Genomic Vision Announces Revenue Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Nov. 06 | Genomic Vision Files for Receivership at French Court | MT |
| Sales 2022 | 1.48 M 1.61 M | Sales 2023 * | - | Capitalization | 2.50 M 2.71 M |
|---|---|---|---|---|---|
| Net income 2022 | -6.00 M -6.52 M | Net income 2023 * | - | EV / Sales 2022 | 2,82x |
| Net Debt 2022 | 1.68 M 1.82 M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | -0,38x | P/E ratio 2023 * | Employees | 33 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 97.86% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +5.88% | ||
| 3 months | -77.78% | ||
| 6 months | -87.23% | ||
| Current year | -95.01% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.05
1 year
0.000.06
3 years
0.001.05
5 years
0.002.19
10 years
0.0017.65
| Managers | Title | Age | Since |
|---|---|---|---|
Aaron Bensimon
CEO | Chief Executive Officer | - | 2004 |
Lionel Seltz
DFI | Director of Finance/CFO | - | 2022 |
Thierry Huet
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mohammed Afshar
BRD | Director/Board Member | - | 2022 |
Aaron Bensimon
CEO | Chief Executive Officer | - | 2004 |
Florence Alouch
CHM | Chairman | - | 2022 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 0.001800 | -.--% | 0 |
| 23-11-30 | 0.001800 | -.--% | 0 |
| 23-11-29 | 0.001800 | -.--% | 0 |
| 23-11-28 | 0.001800 | -.--% | 0 |
| 23-11-27 | 0.001800 | -.--% | 0 |
Real-time Euronext Paris, November 03, 2023 at 12:35 pm EDT
More quotes
Genomic Vision specializes in developing genetic diseases diagnosis tests and cancer genomic analysis. The group uses molecular combing technology which allows direct visualization of DNA individual molecules in order to detect the quantitative and qualitative changes of the genome and determine their role in targeted pathology. The activity is organized around 3 sources of income:
- sales of equipment and consumables: to academic laboratory centers using the molecular combing technology for research purposes;
- license and royalties income: income from collaboration with Quest Diagnostics;
- sales of software, testing kits and related consumables.
Calendar
2024-02-28
- Q4 2023 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| -95.01% | 752 574 $ | |
| +65.53% | 40 132 M $ | |
| +5.87% | 39 586 M $ | |
| -55.56% | 30 438 M $ | |
| -26.79% | 28 571 M $ | |
| +38.66% | 22 175 M $ | |
| -27.87% | 21 511 M $ | |
| +1.62% | 17 412 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ |
